


PRODUCT INFORMATION



Carbidopa-d₃ (hydrate)

Item No. 34884

CAS Registry No.: 1276197-58-0
Formal Name: (αS)-α-hydrazinyl-3,4-dihydroxy-α-methyl-benzenepropanoic-2,5,6-d₃ acid, monohydrate
MF: C₁₀H₁₁D₃N₂O₄ • H₂O
FW: 247.3
Chemical Purity: ≥98% (Carbidopa)
Deuterium Incorporation: ≥99% deuterated forms (d₁-d₃); ≤1% d₀
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Carbidopa-d₃ (hydrate) is intended for use as an internal standard for the quantification of carbidopa (Item No. 23783) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Carbidopa-d₃ (hydrate) is supplied as a solid. A stock solution may be made by dissolving the carbidopa-d₃ (hydrate) in the solvent of choice, which should be purged with an inert gas. Carbidopa-d₃ (hydrate) is slightly soluble in methanol and DMSO.

Description

Carbidopa is a peripherally restricted inhibitor of dopamine decarboxylase, the enzyme that converts L-DOPA (Item No. 13248) to dopamine.¹ Administration of carbidopa (100 mg/kg) prior to administration of L-DOPA in dogs increases the plasma concentration of L-DOPA by 186% and prolongs the half-life in plasma by 48% and skeletal muscle extracellular fluid by 66%.² Carbidopa also binds to and potentiates the activity of the aryl hydrocarbon receptor (AhR).³ It inhibits the proliferation of pancreatic cancer cells *in vitro* and tumor growth *in vivo*. Formulations containing carbidopa are used in combination with L-DOPA in the treatment of Parkinson's disease to increase the amount of dopamine in the brain and reduce peripheral side effects associated with L-DOPA administration.

References

1. Clark, W.G., Oldendorf, W.H., and Dewhurst, W.G. Blood-brain barrier to carbidopa (MK-486) and Ro 4-4602, peripheral dopa decarboxylase inhibitors. *J. Pharm. Pharmacol.* **25(5)**, 416-418 (1973).
2. Deleu, D., Sarre, S., Ebinger, G., *et al.* The effect of carbidopa on the pharmacokinetics and metabolism of intravenously administered levodopa in blood plasma and skeletal muscle. *Naunyn Schmiedebergs Arch. Pharmacol.* **348(6)**, 576-581 (1993).
3. Ogura, J., Miyauchi, S., Shimono, K., *et al.* Carbidopa is an activator of aryl hydrocarbon receptor with potential for cancer therapy. *Biochem J.* **474(20)**, 3391-3402 (2017).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/08/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM